OncoMed Pharmaceuticals achieved two milestones from Celgene Corp. totaling $70 million based on analysis of Phase Ib and interim Phase II clinical trial safety data associated with the demcizumab (anti-DLL4, OMP-21M18) program.    The data from the pancreatic, non-small cell lung and ovarian cancer clinical trials showed no demcizumab-related Grade 3 or higher cardio-pulmonary toxicities among 155 patients treated.  Of those, 68 patients have received at least two cycles of demcizumab at the ...